|
|
Article: New Study Reports Results of PegIntron and Rebetol Combination Therapy in Difficult-to-Treat Hepatitis C Virus (HCV) Genotype 4; Predominant Virus Type in the Middle East.
- Article from:
- PR Newswire Europe
- Article date:
- October 1, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BRUSSELS, Belgium, October 1 /PRNewswire/ --
- Study in Middle Eastern Populations Published in American Journal of Gastroenterology
Patients infected with chronic hepatitis C virus (HCV) genotype 4 can be treated effectively and safely with individualised, weight-based PegIntron(R) (peginterferon alfa-2b) and Rebetol(R) (ribavirin) combination therapy, according to results of a new study published in the American Journal of Gastroenterology(1). HCV genotype 4, one of the more difficult-to-treat strains of the virus, is the most predominant variant of the hepatitis C virus in the Middle East and North Africa(2-4), where the prevalence of HCV infection is ...